Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35129 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Alexander D Sherry und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Disease Progression, Neoplasms, Clinical Trials, Phase III as Topic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NIBIB NIH HHS, Andrew Sabin Family Foundation.
Abstract (Originalsprache)
Disease progression in clinical trials is commonly defined by radiologic measures. However, clinical progression may be more meaningful to patients, may occur even when radiologic criteria for progression are not met, and often requires a change in therapy in clinical practice. The objective of this study was to determine the utilization of clinical progression criteria within progression‐based trial endpoints among phase III trials testing systemic therapies for metastatic solid tumors. The primary manuscripts and protocols of phase III trials were reviewed for whether clinical events, such as refractory pain, tumor bleeding, or neurologic compromise, could constitute a progression event. Univariable logistic regression computed odds ratios (OR) and 95% CI for associations between trial‐level covariates and clinical progression. A total of 216 trials enrolling 148,190 patients were included, with publication dates from 2006 through 2020. A major change in clinical status was included in the progression criteria of 13% of trials ( n = 27), most commonly as a secondary endpoint ( n = 22). Only 59% of trials ( n = 16) reported distinct clinical progression outcomes that constituted the composite surrogate endpoint. Compared with other disease sites, genitourinary trials were more likely to include clinical progression definitions (16/33 [48%] vs. 11/183 [6%]; OR, 14.72; 95% CI, 5.99 to 37.84; p < .0001). While major tumor‐related clinical events were seldom considered as disease progression events, increased attention to clinical progression may improve the meaningfulness and clinical applicability of surrogate endpoints for patients with metastatic solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Insitro, South San Francisco, California, USA.
- Department of Biomedical Informatics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Radiation Oncology, Stanford University, Stanford, California, USA.
- Department of Radiation Oncology and Applied Sciences, Dartmouth Cancer Center, Geisel School of Medicine, Lebanon, New Hampshire, USA.
ORCID-Profile: Alexander D Sherry, Timothy A Lin, Zachary R McCaw, Ramez Kouzy, Joseph Abi Jaoude, Avital M Miller, Gabrielle S Kupferman, Clifton David Fuller, Eugene J Koay, Chad Tang, Pavlos Msaouel, Ethan B Ludmir
Förderung
- NIDCR NIH HHS
- NIBIB NIH HHS
- Andrew Sabin Family Foundation
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Sherry, A. D., Lin, T. A., McCaw, Z. R., Beck, E. J., Kouzy, R., Abi Jaoude, J., Passy, A. H., Miller, A. M., Kupferman, G. S., Fuller, C. D., Thomas, C. R., Koay, E. J., Tang, C., Msaouel, P., & Ludmir, E. B. (2024). Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials. International Journal of Cancer. https://doi.org/10.1002/ijc.35129
Vancouver
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, et al. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials. International Journal of Cancer. 2024. doi:10.1002/ijc.35129
BibTeX
@article{Sherry2024,
author = {Sherry, Alexander D and Lin, Timothy A and McCaw, Zachary R and Beck, Esther J and Kouzy, Ramez and Abi Jaoude, Joseph and Passy, Adina H and Miller, Avital M and Kupferman, Gabrielle S and Fuller, Clifton David and Thomas, Charles R and Koay, Eugene J and Tang, Chad and Msaouel, Pavlos and Ludmir, Ethan B},
title = {Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35129}
}
EUVIMED